Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.39 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | AKT2 | P31751 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411505 | 0.93 | CTSS (0.39) | DRD2UTS2RCTSSCTSK | |
| SCHEMBL6410157 | 0.92 | CACNA1G (0.42) | CTSSCTSKPPARGPPARA | |
| SCHEMBL6409321 | 0.91 | UTS2R (0.42) | DRD2UTS2RWDR91 | |
| SCHEMBL6412682 | 0.91 | DRD2 (0.37) | DRD2CTSSCTSKROCK2 | |
| SCHEMBL6408481 | 0.90 | DRD2 (0.41) | DRD2UTS2RWDR91AKT1 | |
| SCHEMBL6409182 | 0.88 | HPGD (0.35) | DRD2UTS2RCTSSCTSK | |
| SCHEMBL6417456 | 0.88 | CTSS (0.37) | DRD2CTSSCTSK | |
| SCHEMBL6408359 | 0.87 | ALDH1A1 (0.41) | DRD2UTS2RGAAPPARGPPARA | |
| SCHEMBL6408718 | 0.87 | ROCK2 (0.42) | DRD2ROCK2 | |
| SCHEMBL6408469 | 0.85 | DRD2 (0.41) | DRD2CTSSCTSKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | DRD2 1775/4885UTS2R 126/4885WDR91 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.